Search Result

Results for "

ileal

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apical Sodium-Dependent Bile Acid Transporter (7) 5-HT Receptor (1) Acetyl-CoA Carboxylase (2) ACSL Family (2) Adrenergic Receptor (1) Bacterial (1) Calcium Channel (1) Cholecystokinin Receptor (1) CRFR (1) Drug Derivative (2) FXR (2) GLP Receptor (1) Isotope-Labeled Compounds (2) Leukotriene Receptor (1) mAChR (5) Opioid Receptor (1) Reference Standards (2) Toll-like Receptor (TLR) (1)
By Research Areas:	Cardiovascular Disease (4) Infection (1) Inflammation/Immunology (4) Metabolic Disease (16) Neurological Disease (5)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Targets Recommended: Apical Sodium-Dependent Bile Acid Transporter

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-109120

Odevixibat 4 Publications Verification A4250	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease
Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-N0468

Rebaudioside D 1 Publications Verification	FXR Acetyl-CoA Carboxylase	Metabolic Disease
Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-16747

Maralixibat chloride SHP625 chloride; LUM001 chloride; Lopixibat chloride	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease
Maralixibat (SHP625) chloride is an orally active ileal bile acid transporter (IBAT) inhibitor. Maralixibat chloride can be used for the research of rare cholestatic liver diseases including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia .

HY-D1056A2

Lipopolysaccharides, from E. coli O127:B8 LPS, from Escherichia coli (O127:B8)	Toll-like Receptor (TLR)	Inflammation/Immunology
Lipopolysaccharides, from E. coli O127:B8 (LPS, from Escherichia coli (O127:B8)) are endotoxins and TLR4 activators extracted from Escherichia coli (E. coli O127:B8) and are classified as S (smooth) type LPS. Lipopolysaccharides, from E. coli O127:B8 possess the typical three-part structure: O-antigen, R3-type core oligosaccharide, and lipid A. Lipopolysaccharides, from E. coli O127:B8 activate TLR-4 in immune cells, can induce inflammatory responses and ileal contractility, and can be used to construct intestinal inflammation models . It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.

HY-117040

nor-Binaltorphimine Maximum Cited Publications 7 Publications Verification Norbinaltorphimine; NorBNI	Opioid Receptor	Neurological Disease
nor-Binaltorphimine (Norbinaltorphimine; NorBNI) is a selective, long-acting competitive antagonist of the κ-opioid receptor. nor-Binaltorphimine blocks κ-opioid receptor-mediated analgesic effects, and inhibits butorphanol-induced changes in κ-opioid receptor binding kinetics, desensitization and down-regulation. nor-Binaltorphimine suppresses specific opioid withdrawal symptoms, precipitates withdrawal behaviors in butorphanol-dependent rats, and serves as a molecular probe for studying κ-opioid receptor-agonist interactions. nor-Binaltorphimine is applicable to research related to neurological disorders such as pain .

HY-P1108A

Astressin 2B TFA 1 Publications Verification	CRFR	Neurological Disease Inflammation/Immunology
Astressin 2B TFA is a blood-brain barrier-impermeable, highly selective CRFR2 antagonist (rCRFR2, IC₅₀=0.57 nM). Astressin 2B TFA blocks the protective effects mediated by CRFR2, thereby exacerbating indomethacin (HY-14397)-induced hemorrhagic intestinal injury in rats. Astressin 2B TFA reverses the protective effects of Urocortin 1 against intestinal hypermotility, bacterial invasion and upregulation of inflammatory mediators. Astressin 2B TFA also blocks the anxiogenic effect of Urocortin 2 and attenuates stress-induced anxiety-related behaviors. In the Clostridioides difficile toxin A (C. difficile toxin A)-mediated enteritis model, Astressin 2B TFA mimics the phenotype of CRFR2-deficient mice, significantly exacerbating intestinal epithelial damage, edema, neutrophil migration and the expression of multiple proinflammatory cytokines. Astressin 2B TFA is an important tool molecule for investigating the intestinal protective mechanisms of CRFR2 .

HY-N5016

Guvacoline hydrochloride	mAChR	Cardiovascular Disease
Guvacoline hydrochloride, a pyridine alkaloid found in Areca triandra, can act as a weak full agonist of atrial and ileal muscarinic receptors .

HY-116490

Guvacoline hydrobromide	mAChR	Cardiovascular Disease
Guvacoline hydrobromide, a pyridine alkaloid found in Areca triandra, can act as a weak full agonist of atrial and ileal mAChR .

HY-19264

264W94	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease
264W94 is a potent ileal bile acid transporter (IBAT) inhibitor and a new cholesterol lowering agent. 264W94 has CYP7A1 induction, and antilipemic action .

HY-111918

A71378	Cholecystokinin Receptor	Metabolic Disease
A71378 is a selectivity CCK-A receptor agonist the IC₅₀ values of 0.4 nM, 300 nM, and 1,200 nM for the pancreatic CCK-A, cortical CCK-B, and gastrin receptor, respectively. A71378 elicits pancreatic amylase secretion (EC₅₀ = 0.16 nM) and ileal muscle contraction (EC₅₀ = 3.7 nM) .

HY-116680

LY53857	5-HT Receptor	Cardiovascular Disease Neurological Disease
LY53857 is a potent antagonist of vasoconstriction and serotonin-mediated 5-HT₂ receptors. LY53857 did not reduce mean arterial blood pressure in spontaneously hypertensive rats (SHR) at doses that blocked the depressor response to serotonin and blocked central serotonin receptors. In addition, LY53857 was able to enhance neurotransmitter release in rat vas deferens and guinea pig ileal nerves .

HY-136634

BTM-1042	mAChR	Others
BTM-1042 is a newly synthesized compound with antispasmodic effects. It can inhibit the twitch reaction of the guinea pig ileum under electrical stimulation and is not affected by naloxone. It has similar effects to atropine and can block muscarinic receptors, but has less effect on other types of receptors. BTM-1042 also has an inhibitory effect on the ileal reaction caused by nicotine and 5-hydroxytryptamine. BTM-1042 showed a dose-dependent inhibitory effect on the spontaneous movement of the rabbit stomach. In general, BTM-1042 is a agent with a strong antispasmodic effect.

HY-N0468R

Rebaudioside D (Standard)	Reference Standards Acetyl-CoA Carboxylase FXR	Metabolic Disease
Rebaudioside D (Standard) is the analytical standard of Rebaudioside D. This product is intended for research and analytical applications. Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-19298

S-8921	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease
S-8921 is an ileal Na ⁺/bile acid cotransporter (IBAT) inhibitor.

HY-120418

L-687306	mAChR	Others
L-687306 is a high affinity muscarinic M1 receptor partial agonist with activity as a partial agonist of M1 receptors in rat ganglia and as a high affinity competitive antagonist at guinea pig cardiac M2 and ileal M3 muscarinic receptors, useful for studying the receptor reserve of muscarinic receptors.

HY-109120S

Odevixibat-d5 A4250-d₅	Apical Sodium-Dependent Bile Acid Transporter Isotope-Labeled Compounds	Metabolic Disease
Odevixibat-d₅ is deuterated labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-109120R

Odevixibat (Standard) A4250 (Standard)	Apical Sodium-Dependent Bile Acid Transporter Reference Standards	Metabolic Disease
Odevixibat (Standard) is the analytical standard of Odevixibat. This product is intended for research and analytical applications. Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-109120S1

Odevixibat-13C6 A4250-¹³C₆	Apical Sodium-Dependent Bile Acid Transporter Isotope-Labeled Compounds	Metabolic Disease
Odevixibat- ¹³C₆ is ¹³C labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-16489A

Terodiline hydrochloride	mAChR Calcium Channel	Neurological Disease
Terodiline hydrochloride is an M1-selective muscarinic receptor (mAChR) antagonist with K_bs of 15, 160, 280, and 198 nM in rabbit vas deferens (M1), atria (M2), bladder (M3) and ileal muscle (M3), respectively. Terodiline hydrochloride also is a Ca ²⁺ blocker. Terodiline hydrochloride acts as a treatment for urinary frequency and urge incontinence .

HY-P11149

Human Defensin-5 (1-9)	Bacterial	Infection Metabolic Disease
Human Defensin-5 (1-9) is an orally active antimicrobial peptide. Human Defensin-5 (1-9) can inhibit metabolic disorders induced by Western-style diet (WSD) or Western-style diet with fructose (WSDF). Human Defensin-5 (1-9) enhances intestinal barrier function by upregulating the gene expression of ileal tight junction protein and mucins. Human Defensin-5 (1-9) can be used for the study of obesity and related metabolic diseases .

HY-182515

U-19052	Leukotriene Receptor	Others Inflammation/Immunology
U-19052 is a selective competitive peptidoleukotriene D/E receptor antagonist. U-19052 acts as a reversible antagonist that not affecting responses to non-leukotriene agonists. U-19052 does not exhibit agonist activity or induce contraction in guinea pig tracheal or ileal strips. U-19052 is a leukotriene antagonist developed by modifying leukotriene chemical structure. U-19052 can be used for the research of allergic asthma and hypersensitivity diseases .

HY-186095

LP-911888	ACSL Family	Metabolic Disease
LP-911888 is an orally active ACSL5/ACSL1 inhibitor, with IC₅₀ values of 1 nM and 3 nM against mouse and human ACSL5, and IC₅₀ values of 2 nM and 9 nM against mouse and human ACSL1, respectively. LP-911888 inhibits intestinal triglyceride uptake; it also reduces body weight and food consumption in diet-induced obese mice, and delays gastric emptying by activating the ileal brake pathway. LP-911888 can be used in studies of diet-induced obesity .

HY-182640

SM-11044	Adrenergic Receptor	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
SM-11044 is a β-adrenoceptor agonist with K_i values of 18.1 μM (β₁), 4.1 μM (β₂) and 1.3 μM (β₃), showing higher binding selectivity for the β₃-adrenoceptor. SM-11044 stimulates cAMP accumulation in cells expressing this receptor. SM-11044 mediates ileal relaxation, tracheal relaxation, pulmonary parenchymal relaxation, increased right atrial heart rate and adipocyte lipolysis .

HY-186096

LP-856866	ACSL Family GLP Receptor	Metabolic Disease
LP-856866 is an orally active ACSL5 inhibitor, with IC₅₀ values of 8 nM and 4 nM against mouse and human ACSL5, respectively, and IC₅₀ values of 6 nM and 17 nM against mouse and human ACSL1, respectively. LP-856866 induces delayed gastric emptying, promotes GLP-1 release, reduces food intake, decreases body weight and body fat mass, preserves lean body mass, improves glucose homeostasis, enhances insulin sensitivity, reduces hepatic lipid accumulation, and lowers serum triglyceride and total cholesterol levels. LP-856866 is applicable to research on diet-induced obesity .

HY-N18490

5α-Cyprinol sulfate	Drug Derivative	Metabolic Disease
5α-Cyprinol sulfate is an orally active bile salt and heterospecific pheromone. 5α-Cyprinol sulfate promotes lipid digestion in fish. 5α-Cyprinol sulfate inhibits taurocholic acid uptake mediated by apical bile salt transporters in rat ileum. 5α-Cyprinol sulfate can be used in studies of fish toxic acute renal failure .

HY-176961

Homocholic acid	Drug Derivative	Metabolic Disease
Homocholic acid is a synthetic steroid analogue. Homocholic acid can be labeled with 75Se and is used for SeHCAT detection (a method for diagnosing bile acid malabsorption) .

Cat. No.	Product Name	Type

HY-D1056A2

Lipopolysaccharides, from E. coli O127:B8 LPS, from Escherichia coli (O127:B8)	Biochemical Assay Reagents
Lipopolysaccharides, from E. coli O127:B8 (LPS, from Escherichia coli (O127:B8)) are endotoxins and TLR4 activators extracted from Escherichia coli (E. coli O127:B8) and are classified as S (smooth) type LPS. Lipopolysaccharides, from E. coli O127:B8 possess the typical three-part structure: O-antigen, R3-type core oligosaccharide, and lipid A. Lipopolysaccharides, from E. coli O127:B8 activate TLR-4 in immune cells, can induce inflammatory responses and ileal contractility, and can be used to construct intestinal inflammation models . It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.

Lipopolysaccharides, from E. coli O127:B8

LPS, from Escherichia coli (O127:B8)

Biochemical Assay Reagents

Lipopolysaccharides, from E. coli O127:B8 (LPS, from Escherichia coli (O127:B8)) are endotoxins and TLR4 activators extracted from Escherichia coli (E. coli O127:B8) and are classified as S (smooth) type LPS. Lipopolysaccharides, from E. coli O127:B8 possess the typical three-part structure: O-antigen, R3-type core oligosaccharide, and lipid A. Lipopolysaccharides, from E. coli O127:B8 activate TLR-4 in immune cells, can induce inflammatory responses and ileal contractility, and can be used to construct intestinal inflammation models .
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.

Cat. No.	Product Name	Target	Research Area

HY-P1108A

Astressin 2B TFA 1 Publications Verification	CRFR	Neurological Disease Inflammation/Immunology
Astressin 2B TFA is a blood-brain barrier-impermeable, highly selective CRFR2 antagonist (rCRFR2, IC₅₀=0.57 nM). Astressin 2B TFA blocks the protective effects mediated by CRFR2, thereby exacerbating indomethacin (HY-14397)-induced hemorrhagic intestinal injury in rats. Astressin 2B TFA reverses the protective effects of Urocortin 1 against intestinal hypermotility, bacterial invasion and upregulation of inflammatory mediators. Astressin 2B TFA also blocks the anxiogenic effect of Urocortin 2 and attenuates stress-induced anxiety-related behaviors. In the Clostridioides difficile toxin A (C. difficile toxin A)-mediated enteritis model, Astressin 2B TFA mimics the phenotype of CRFR2-deficient mice, significantly exacerbating intestinal epithelial damage, edema, neutrophil migration and the expression of multiple proinflammatory cytokines. Astressin 2B TFA is an important tool molecule for investigating the intestinal protective mechanisms of CRFR2 .

HY-P3826

Chromogranin A (324-337), human	Peptides	Neurological Disease
Chromogranin A (324-337), human is a peptide fragment of chromogranin A, it can be isolated from human ileal carcinoid tumor. Chromogranin A is a soluble glycoprotein stored with hormones and neuropeptides in secretory granules of most (neuro)endocrine cells and neurons, and it is also a plasma marker of neuroendocrine tumors .

HY-P11149

Human Defensin-5 (1-9)	Bacterial	Infection Metabolic Disease
Human Defensin-5 (1-9) is an orally active antimicrobial peptide. Human Defensin-5 (1-9) can inhibit metabolic disorders induced by Western-style diet (WSD) or Western-style diet with fructose (WSDF). Human Defensin-5 (1-9) enhances intestinal barrier function by upregulating the gene expression of ileal tight junction protein and mucins. Human Defensin-5 (1-9) can be used for the study of obesity and related metabolic diseases .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0468

Rebaudioside D 1 Publications Verification	Structural Classification other families Classification of Application Fields Terpenoids Metabolic Disease Diterpenoids Plants Disease Research Fields Sweeteners Source Classification Food Research	FXR Acetyl-CoA Carboxylase
Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-N5016

Guvacoline hydrochloride	Cardiovascular Disease Alkaloids Classification of Application Fields Pyridine Alkaloids Plants Palmae Areca triandra Roxb. Disease Research Fields Source Classification	mAChR
Guvacoline hydrochloride, a pyridine alkaloid found in Areca triandra, can act as a weak full agonist of atrial and ileal muscarinic receptors .

HY-N0468R

Rebaudioside D (Standard)	Structural Classification other families Terpenoids Diterpenoids Plants Source Classification	Reference Standards Acetyl-CoA Carboxylase FXR
Rebaudioside D (Standard) is the analytical standard of Rebaudioside D. This product is intended for research and analytical applications. Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-N18490

5α-Cyprinol sulfate	Structural Classification Animals Steroids Source Classification	Drug Derivative
5α-Cyprinol sulfate is an orally active bile salt and heterospecific pheromone. 5α-Cyprinol sulfate promotes lipid digestion in fish. 5α-Cyprinol sulfate inhibits taurocholic acid uptake mediated by apical bile salt transporters in rat ileum. 5α-Cyprinol sulfate can be used in studies of fish toxic acute renal failure .

Species:	Human (3)
Tag:	His (3)
Source:	HEK293 (2) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P77450

	NAALADL1 Protein, Human (HEK293, His) Aminopeptidase NAALADL1; I100; ileal dipeptidylpeptidase; NAALADASEL; NAALADL	Human	HEK293
	NAALADL1 is an aminopeptidase with broad substrate specificity and shows lower activity towards substrates containing Asp or Glu at the P2' position or Pro at the P3' position. It is worth noting that it lacks activity against substrates with Pro at the P3' position and Asp or Glu at the P2' position. NAALADL1 Protein, Human (HEK293, His) is the recombinant human-derived NAALADL1 protein, expressed by HEK293 , with N-His labeled tag.

HY-P705614

	SLC10A2 Protein-VLP, Human (HEK293, His) Apical sodium-dependent bile acid transporter; ASBT; ileal sodium-dependent bile acid transporter; IBAT; ISBT; Na+; Sodium/taurocholate cotransporting polypeptide, ileal; Solute carrier family 10 member 2	Human	HEK293
	SLC10A2 Protein-VLP, Human (HEK293, His) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P701236. Tags can only be detected under denaturing conditions.

HY-P70160

	Gastrotropin/FABP6 Protein, Human (His) rHuGastrotropin/FABP6, His; Gastrotropin; GT; Fatty Acid-Binding Protein 6; ileal Lipid-Binding Protein; ILBP; Intestinal 15 kDa Protein; I-15P; Intestinal Bile Acid-Binding Protein; I-BABP; FABP6; ILBP; ILLBP	Human	E. coli
	Gastrotropin/FABP6 is a fatty acid binding protein, or ileal bile acid binding protein (IBABP). FABP6 is a therapeutic target related to immune infiltration, and FABP6 inhibition inhibits cancer cell proliferation and migration. Gastrotropin/FABP6 Protein, Human (His) is the recombinant human-derived Gastrotropin/FABP6 protein, expressed by E. coli , with N-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-109120S

Odevixibat-d5
Odevixibat-d₅ is deuterated labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-109120S1

Odevixibat-13C6
Odevixibat- ¹³C₆ is ¹³C labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

ileal

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Natural
Products